Share this article
Share this article
IRVING, Texas, June 3, 2021 /PRNewswire/ Breeze Holdings Acquisition Corp. (NASDAQ: BREZ) (the Company ) announced today that on May 28, 2021 it received a notice ( Notice ) from the Listing Qualifications Department of The Nasdaq Stock Market ( Nasdaq ) stating that the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) (the Rule ) because the Company failed to timely file its Quarterly Report on Form 10-Q for the period ended March 31, 2021 (the Form 10-Q ) with the Securities and Exchange Commission ( SEC ). The Notice has no immediate effect on the listing or trading of the Company s securities on the Nasdaq Capital Market.
Share this article
Share this article
ST. PETERSBURG, Fla., June 3, 2021 /PRNewswire/ Isleworth Healthcare Acquisition Corp. (NASDAQ: ISLE) (the Company ) announced today announced that on May 28, 2021 it received a notice ( Notice ) from the Listing Qualifications Department of The Nasdaq Stock Market ( Nasdaq ) stating that the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) (the Rule ) because the Company failed to timely file its Quarterly Report on Form 10-Q for the period ended March 31, 2021 (the Form 10-Q ) with the Securities and Exchange Commission ( SEC ). The Notice has no immediate effect on the listing or trading of the Company s securities on the Nasdaq Capital Market.
WILMINGTON, Del., June 03, 2021 On April 12, 2021, the Acting Director of the Division of Corporation Finance and Acting Chief Accountant of the U.S. Securities and Exchange Commission . | June 3, 2021
Surrozen Publishes Article in Nature Communications Demonstrating Selective Wnt Mimetics Stimulate Bone Mass Accrual in Disease Models of Osteoporosis, Aging and Long-Bone Fracture
June 01, 2021 08:00 ET | Source: Surrozen, Inc. Surrozen, Inc. South San Francisco, California, UNITED STATES
Results Demonstrate Rapid and Robust Bone-building Effects from Selective Wnt Agonists in Proof of Concept, Preclinical Studies of Wnt Mimetics for the Treatment of Diseases of Low Bone Mineral Density
Studies Validate Potential of Surrozen’s Wnt Antibody Platform
SOUTH SAN FRANCISCO, Calif., June 01, 2021 (GLOBE NEWSWIRE) Surrozen Inc., a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway, announced today the publication of an article in the journal
Posted on 204
Omnichannel Acquisition Corp. (NYSE: OCA) (the “Company”) received written notification from The New York Stock Exchange (“NYSE”) on May 25, 2021 that, because the Company has not yet filed its Quarterly Report on Form 10-Q for the quarter ended March 31, 2021 (the “10-Q”) with the Securities and Exchange Commission (“SEC”), the Company does not comply with the continued listing requirements under Section 802.01E of the Listed Company Manual, which requires NYSE-listed companies to timely file all periodic reports with the SEC. The NYSE informed the Company that the Company has six months from the 10-Q filing due date to file the Form 10-Q. The Notice has no immediate effect on the listing or trading of the Company’s securities on the NYSE.